SAN DIEGO, Jan. 5, 2021 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate
presentation as part of the H.C. Wainwright BioConnect 2021
Conference. The conference, which will take place January 11-14, 2021, is being conducted with a
virtual format.
Details for this presentation are as follows:
- H.C. Wainwright BioConnect 2021 Conference
Conference
Dates: January 11-14, 2021
Presentation Timing: Available online upon start of conference on
Monday, January 11, 2021
Format: Virtual conference; webcast available
A webcast of the H.C. Wainwright presentation may be accessed
via a link on the Viking Therapeutics website in the Investors
& Media section under Webcasts. The webcast will be
available on the Viking website once the conference gets underway
on January 11, 2021.
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical
company focused on the development of novel, orally available,
first-in-class or best-in-class therapies for the treatment of
metabolic and endocrine disorders. Viking's research and
development activities leverage its expertise in metabolism to
develop innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, which is currently being evaluated in a
Phase 2b study for the treatment of biopsy-confirmed
non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase
2 trial for the treatment of non-alcoholic fatty liver disease
(NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the potential treatment of X-linked
adrenoleukodystrophy (X-ALD). VK0214 is currently being
evaluated in a Phase 1 first-in-human clinical trial. The
company holds exclusive worldwide rights to a portfolio of five
therapeutic programs, including those noted above, which are based
on small molecules licensed from Ligand Pharmaceuticals
Incorporated.
For more information about Viking Therapeutics, please visit
www.vikingtherapeutics.com. Follow Viking on Twitter
@Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-hc-wainwright-bioconnect-2021-conference-301201273.html
SOURCE Viking Therapeutics, Inc.